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Once breast cancer cells grow aggressively and become lodged in the skeleton through migration and invasion, they interact with
bone microenvironment and accelerate much more tumor growth and bone destruction. We investigated whether liensinine and
nuciferine, major active components in Nelumbo nucifera (lotus), could prevent breast cancer cell-mediated bone destruction.
Liensinine and nuciferine inhibited the growth of MDA-MB-231 and MCF-7 human breast cancer cells by inducing apoptosis and
inhibiting proliferation via cell cycle arrest. Liensinine treatment led to the increased Bax/Bcl-2 ratio, activation of caspase-3, and
subsequent cleavage of PARP. Liensinine also displayed significant inhibition on the migration and invasion of both MDA-MB-
231 and MCF-7 human breast cancer cells compared with nuciferine. In addition, liensinine and nuciferine inhibited the receptor
activator of nuclear factor kappa-B ligand- (RANKL-) induced osteoclast differentiation in mouse bone marrow macrophage cells
and mature osteoclast-mediated bone resorption. Furthermore, oral administration of liensinine reduced the osteolysis in nude
mice with intratibial injection of MDA-MB-231 cells. Collectively, liensinine and nuciferine may be promising candidates for
preventing and treating breast cancer bone metastasis and the resulting osteolytic bone loss by targeting both cancer cells and
osteoclasts. Liensinine has more potent anticancer and antibone resorptive activities than nuciferine.
1. Introduction
Breast cancer is the common form of cancer in women and
the major cause of cancer deaths worldwide, accounting for
23% of cancer diagnoses and 14% of cancer deaths each
year [1]. Although surgical therapies removing primary breast
cancer have shown beneficial effect, they are not fundamental
solution because most causes of morbidity in breast cancer
are not primary tumors but incurable complications from
bone metastasis, including pathologic fractures, disability,
pain, nerve compression, anemia, and hypercalcemia [2, 3].
Bone is a dynamic organ that continuously undergoes
remodeling processes to maintain mineral homeostasis and
structural robustness [4]. Normal bone remodeling is finely
regulated by balance between osteoblastic bone forma-
tion and osteoclastic bone resorption [5]. Once metastatic
breast cancer cells enter into the bone microenvironment,
they disturb the normal regulatory mechanisms associated
with bone remodeling process by inducing activation of
bone-resorbing osteoclasts [6]. Breast cancer-induced factors
stimulate osteoblastic/stromal cells to produce macrophage-
colony-stimulating factor (M-CSF) for the survival of osteo-
clast precursors and receptor activator of nuclear factor-𝜅B
ligand (RANKL) for osteoclastogenesis [7]. Mature bone-
resorbing osteoclasts secrete hydrogen ion for acidic bone
microenvironment and proteases for the degradation of the
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organic bone matrix. Currently, resorption inhibitors, such
as bisphosphonates and denosumab, are clinically used to
treat the patientswith bonemetastases.However, these agents
targeting osteoclastic activity do not prevent the development
of bonemetastasis and ultimately do not prolong survival [8].
Liensinine and nuciferine (Figure 1(a)) are principal com-
ponents in lotus (Nelumbo nucifera Gaertn, Nymphaeaceae),
which is extensively cultivated in Eastern Asia, particularly in
China, and has been used as remedy for the disorders asso-
ciated with oxidative stress, metabolic syndrome, immunity,
and inflammation [9–11]. Liensinine, a bisbenzylisoquinoline
alkaloid, has been reported to inhibit autophagy and to
increase apoptosis in breast cancer cells cotreated with var-
ious chemotherapeutic agents [12]. Isoliensinine treatment
caused apoptosis through the production of reactive oxygen
species and p38 MAPK/JNK activation in triple-negative
human breast cancer cells [13]. Nuciferine, an aporphine
alkaloid, has been shown to reduce the viability of SY5Y
human neuroblastoma cells and CT26 murine colon cancer
cells and to inhibit tumor growth in nude mice xenografted
with these cancer cell lines [14]. In addition, nuciferine inhib-
ited nicotine-induced non-small-cell lung cancer progression
[15].
In the current study, we attempted to estimate whether
liensinine and nuciferine could prevent breast cancer-
mediated bone destruction by examining their effects on the
growth, motility, and invasiveness of human triple-negative
MDA-MB-231 and human estrogen receptor-positive MCF-7
cells, RANKL-induced osteoclast differentiation in bonemar-
row macrophages (BMMs), and mature osteoclast-mediated
bone resorption. Furthermore, the inhibitory effect of liensi-
nine on the production of breast cancer-induced osteolytic
lesions was determined in mice with intratibial injection of
MDA-MB-231 breast cancer cells.
2. Materials and Methods
2.1. Materials. Liensinine and nuciferine (≥98% by HPLC)
were purchased from ChemFaces (Wuhan, Hubei, China)
and dissolved with dimethyl sulfoxide (DMSO) and ethanol,
respectively. Dulbecco’s modified Eagle medium (DMEM),
minimum essential medium alpha (𝛼-MEM), Dulbecco’s
phosphate-buffered saline (PBS), fetal bovine serum (FBS),
and antibiotic-antimycotic mixture containing 100U/ml
penicillin and 100 𝜇l/ml streptomycin were obtained from
Gibco BRL (Grand Island, NY). 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT), histopaque-
1083, and DMSO were purchased from Sigma-Aldrich (St.
Louis, MO). Anti-human Bcl-2, procaspase-3, caspase-3,
poly(ADP-ribose) polymerase (PARP), andRANKL antibod-
ies were obtained from Cell Signaling Technology (Beverly,
MA). Anti-human Bax and horseradish peroxidase- (HRP-)
conjugated anti-rabbit second antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Recombinant
mouse soluble RANKL (sRANKL) and M-CSF were pur-
chased from R&D system (Minneapolis, MN). All reagents
used in this study were of analytical grade.
2.2. Animals. 5-week-old female Balb/c nu/nu mice and
4-week-old male ICR mice were obtained from the Nara
Biotechnology (Seoul, Korea). All mice were provided with
free access to a commercial rodent chow diet and tap water
andmaintained under specific pathogen-free conditions with
a 12 h light-dark cycle at 22 ± 2∘C. All animal experimental
procedures were conducted in compliance with the guide-
lines and regulations for the use and care of animals estab-
lished by Yonsei University College of Dentistry. All methods
were carried out in accordance with relevant guidelines and
regulations.
2.3. Cell Lines and Cell Cultures. Human breast cancer cells
lines, MDA-MB-231 and MCF-7, were obtained from the
Korean Cell Line Bank (Seoul, Korea) and grown in DMEM
medium supplemented with 10% FBS at 37∘C under a humid-
ified atmosphere of 5% CO2. Mouse BMMs isolated from the
tibiae of 4-week-old ICR mice were cultured with 𝛼-MEM
containing M-CSF (30 ng/ml), 10% FBS, and 1% antibiotic-
antimycotic mixture in a humidified atmosphere of 5% CO2
at 37∘C.
2.4. Cell Viability Assay. MDA-MB-231 or MCF-7 cells (5
× 103 cells/well) were cultured in serum-free media with
the various concentrations of liensinine or nuciferine in the
absence or presence of zVAD-fmk (10 𝜇M) for 24 h. BMMs
(5 × 104 cells/well) were cultured in serum-free medium with
liensinine or nuciferine at the indicated concentrations for 5
days. Cell viability was measured with an MTT assay.
2.5. Transwell Migration and Invasion Assay. Cell migration
and invasion were detected using transwell chamber (Corn-
ing Life Sciences, Corning Costar, MA). For cell migration
assay, the chamberwas coatedwith 10% (w/v) gelatin on lower
surface of polycarbonate membrane (6.5mm in diameter,
8 𝜇m pore size). For cell invasion assay, the chamber was
coated with 10% (w/v) gelatin on lower surface and matrigel
(1mg/ml in distilledwater) on upper surface of polycarbonate
membrane. The upper chamber was filled with MDA-MB-
231 (5 × 104 cells/100 𝜇l) or MCF-7 (1 × 105 cells/100 𝜇l)
cell suspension and serum-free media containing different
concentrations of liensinine or nuciferine.The lower chamber
contained 600 𝜇l of DMEM containing 5% FBS and various
concentrations of liensinine or nuciferine. After 24 h of
incubation, migrated or invaded cells at the lower surface of
the membrane were counted as previously described [16, 17].
2.6. Apoptosis andNecrosis Assay. Apoptotic and necrotic cell
death was measured using the Cell Death Detection ELISA
Kit (Roche Diagnostics, Mannheim, Germany) according
to the manufacturer’s instruction. Briefly, MDA-MB-231 or
MCF-7 cells (5 × 103 cells/well) were treated with the various
concentrations of liensinine or nuciferine in serum-free
media for 24 h. After centrifugation at 200×g for 10min, the
supernatants were collected and the cells were incubated with
lysis buffer for 30min at room temperature.The supernatants
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Figure 1: Liensinine and nuciferine inhibited the viability, migration, and invasion of breast cancer cells. (a) Chemical structures of liensinine
and nuciferine. (b) MDA-MB-231 or MCF-7 cells were treated with various concentrations of liensinine and nuciferine in serum-free media
for 24 h. Cell viability was determined by anMTT assay. (c) In the presence of liensinine or nuciferine at the indicated concentrations, MDA-
MB-231 or MCF-7 cells were added to transwell chamber and attracted by 5% FBS for 24 h. (d) MDA-MB-231 or MCF-7 cells were seeded
into the matrigel-based upper chamber with serum-free media containing liensinine or nuciferine. The lower chamber was filled with 600𝜇l
of media containing 5% FBS and liensinine or nuciferine for 24 h. Data are expressed as the mean ± SE. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001 versus
untreated cells.
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and cell lysates were incubated in the anti-histone antibody-
coated wells of a microplate for 2 h. Absorbance was mea-
sured at 405 nm using a Benchmark Microplate Reader.
2.7. Cell Proliferation Assay. MDA-MB-231 or MCF-7 cells
(5 × 103 cells/well) were treated with the various concen-
trations of liensinine or nuciferine in serum-free media for
24 h. The amount of incorporated 5-bromo-2-deoxyuridine
(BrdU) into newly synthesized DNA of proliferating cells
was detected using a BrdU cell proliferation assay kit (Roche
Applied Science, Penzberg, Germany). Absorbance was mea-
sured at a wavelength of 450 nm in a Benchmark Microplate
Reader.
2.8. Cell Cycle Distribution Analysis. MDA-MB-231 or MCF-
7 cells (5 × 105 cells) were treated with different concentra-
tions of liensinine or nuciferine in serum-free media for 24 h.
The cells were harvested, washed with PBS, and fixed with
ice-cold 70% ethanol overnight at 4∘C.The cells were washed
with PBS again and incubated in solution containing 1mg/ml
RNase A, 0.1% Triton-X, and 0.1mg/ml propidium iodide at
room temperature in the dark for 30min. DNA content was
then analyzed using flow cytometer (BD Bioscience, Franklin
Lakes, NJ).
2.9. Western Blot Analysis. MDA-MB-231 or MCF-7 cells in
100mm culture dishes were treated with different concentra-
tions of liensinine in serum-freemedia for 24 h and then lysed
with RIPA buffer (Cell Signaling Technology) containing
1mM phenylmethylsulfonyl fluoride and protease inhibitor
cocktail (Roche, Mannheim, Germany). Cell lysates were
centrifuged at 22,000×g for 15min at 4∘C and the protein
concentration in the supernatant was determined using the
BCA protein assay kit (Pierce, Rockford, IL). Equal amounts
of protein (40𝜇g) were subjected to electrophoresis on
sodium dodecyl sulfate- (SDS-) polyacrylamide gels and the
blots on the gel were transferred to the polyvinylidene diflu-
oride membrane (Millipore, Billerica, MA). The membranes
were blocked with 10% skimmilk for 1 h at room temperature
and then were incubated with the specific primary antibody
against target proteins in 3% skimmilk at a dilutions specified
by the manufacturer. After washing with TBS-T (10mM Tris,
pH 8.0, 150mM NaCl, and 0.1% Tween-20), the membrane
was incubated with the respective horseradish peroxidase-
conjugated secondary antibody at 1 : 2,000 dilutions for 1 h
at room temperature. The target protein was detected using
Enhanced Chemiluminescence kit (Amersham, Piscataway,
NJ) according to manufacturer’s protocol.
2.10. Osteoclast Formation Assay. BMMs (5 × 104 cells/well)
were incubated with 𝛼-MEM containing 10% FBS, M-CSF
(30 ng/ml), sRANKL (100 ng/ml), and different concentra-
tions of liensinine or nuciferine for 5 days. The media were
replaced with fresh media every second day. The cells were
stained using the Acid Phosphatase Leukocyte kit (Sigma-
Aldrich) and tartrate-resistant acid phosphatase- (TRAP-
) positive multinucleated osteoclasts with more than three
nuclei were counted under light microscopy (×100 magnifi-
cation) as described previously [16, 17].
2.11. Pit Formation Assay. BMMs (5 × 104 cells/well) were
seeded into an Osteo assay plate (Corning, NY) and cultured
with 𝛼-MEM containing 10% FBS, M-CSF (30 ng/ml), and
sRANKL (100 ng/ml) for 5 days. BMMs were then treated
with liensinine or nuciferine at the indicated concentrations
for 2 additional days.The activities of cathepsin K andmatrix
metalloproteinases (MMPs) in the collectedmedia weremea-
sured using SensiZyme cathepsin K assay kit (Sigma-Aldrich)
and gelatin zymography, respectively, and the resorbed pits
on the plate were observed under light microscope (×100
magnification), as previously described [16, 17].
2.12. A Murine Model of Breast Cancer-Induced Osteolysis.
Female Balb/c nu/nu mice were randomly divided into 6
groups, with 6mice per group.Themice were anesthetized by
intraperitoneal injection of a mixture with 30mg/kg Zoletil
(Virbac Laboratories, Carros, France) and 10mg/kg Rompun
(Bayer HealthCare Korea, Seoul, Korea) mixture. MDA-MB-
231 cells (1 × 106 cells/0.5ml HBSS) were injected into the
medullar cavity of the proximal tibia of the mice using a
Hamilton syringe and 27-gauge needle. From the next day,
liensinine at 5, 10, or 20mg/kg of body weight (BW) was
orally administered 5 times per week and zoledronic acid
at 0.1mg/kg BW was subcutaneously injected 3 times per
week for 5 weeks. Control and MDA-MB-231 cell alone-
inoculated mice received vehicle (PBS containing 1% DMSO)
instead of liensinine. For histological examination, tibiae and
femora of mice were fixed in 10% buffered formalin solution
at 4∘C for a week. Tibiae and femora were decalcified with
10% EDTA solution (pH 7.5) at 4∘C for two weeks and then
embedded in paraffin. Serial sections (3–5 𝜇m thick) were
stainedwith hematoxylin-eosin (H&E) as describe previously
[18]. The tibia of mice was analyzed with microcomputed
tomography (micro-CT) system (SkyScan 1076, SkyScan,
Kontich, Belgium) with 100 kV, 140 𝜇A current, and rotation
step 0.6∘. Scans were reconstructed in the NRecon software
(SkyScan). Bone morphometric parameters were analyzed
in the proximal tibiae of nude mice using CTAn software
(SkyScan). The serum levels of tartrate-resistant acid phos-
phatase (TRAP) 5b and C-terminal cross-linking telopeptide
of type I collagen (CTX) were quantified using mouse TRAP
assay kit (Immunodiagnostic Systems, Boldon, UK) and
RatLaps EIA kit (Immunodiagnostic Systems) according to
the manufacturer’s instructions, respectively.
2.13. Statistics Analysis. Data were expressed as mean ±
standard error (SE) of three independent experiments. Sta-
tistical analysis was performed with a one-way ANOVA and
Student’s 𝑡-test to express the difference between the two
groups. If the 𝑃 value is under 0.05, results are considered
statistically significant.
3. Results
3.1. Liensinine and Nuciferine Decreased the Viability, Migra-
tion, and Invasion of Breast Cancer Cells. When MDA-
MB-231 and MCF-7 cells were incubated with increasing
doses of liensinine and nuciferine for 24 h, their viability
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was decreased in a dose-dependent manner (Figure 1(b)).
Liensinine and nuciferine at 60 𝜇M reduced cell viability by
50% and 40% in MDA-MB-231 cells and by 40% and 20%
in MCF-7 cells, respectively. In addition, the migration assay
using transwell chamber indicated that liensinine at 60𝜇M
inhibited cell migration by 72% in MDA-MB-231 cells and
by 61% in MCF-7 cells (Figure 1(c)). However, nuciferine
did not show significant inhibition in both cell lines. The
invasion of MDA-MB-231 and MCF-7 cells was inhibited by
76% and 56% by liensinine treatment at 60 𝜇M, respectively.
Nuciferine treatment at 60 𝜇Mreduced the invasion ofMDA-
MB-231 cells by 52% but not that ofMCF-7 cells (Figure 1(d)).
3.2. Liensinine and Nuciferine Induced the Apoptosis and
Inhibited Cell Proliferation in Breast Cancer Cells. To inves-
tigate whether the liensinine and nuciferine could induce
apoptosis in MDA-MB-231 and MCF-7 cells, histone-
associated DNA fragments were measured in lysate (apop-
tosis) and culture supernatants (necrosis) of the cells treated
with the various concentrations of liensinine and nuciferine
for 24 h using the Cell DeathDetection ELISAKit. Liensinine
treatment induced apoptosis in a dose-dependent manner
and sharply increased particularly at 60 𝜇M inMDA-MB-231
cells. In contrast, apoptosis was slightly induced in liensinine-
treatedMCF-7 cells and nuciferine-treated breast cancer cells
(Figure 2(a)). Treatment with liensinine and nuciferine at
60 𝜇M and less did not cause necrosis in two breast cancer
cell lines.
Next, we examined the inhibitory effects of liensinine and
nuciferine on cell proliferation by measuring the amount of
incorporated BrdU into DNA in MDA-MB-231 and MCF-7
cells treated with each compound for 24 h. Liensinine and
nuciferine inhibited the incorporation of BrdU in these breast
cancer cells in a dose-dependentmanner. Liensinine at 60𝜇M
decreased BrdU incorporation by 58% and 70% in MDA-
MB-231 and MCF-7 cells, respectively. Nuciferine at 60𝜇M
reduced BrdU incorporation by 37% and 27% in MDA-MB-
231 and MCF-7 cells, respectively (Figure 2(b)).
We further analyzed cell cycle distribution in breast
cancer cells treated with liensinine and nuciferine in serum-
free media for 24 h. Flow cytometric analysis indicated that
treatment with liensinine dose-dependently increased sub-
G1 peak as an indicator of apoptotic cell death and cell
population at G2/M phase inMDA-MB-231 andMCF-7 cells.
Nuciferine slightly increased sub-G1 peak in both cell lines
but induced G1 arrest in MDA-MB-231 cells and G2 arrest
inMCF-7 cells. However, nuciferine did not show substantial
effect (Figure 2(c)).
3.3. Liensinine Induced Caspase-Dependent Apoptosis in
Breast Cancer Cells. We attempted to verify the molecular
mechanism by which apoptosis is induced in MDA-MB-
231 and MCF-7 cells treated with liensinine for 24 h. In
the presence of caspase inhibitor zVAD-fmk, cell viability
was recovered in breast cancer cells treated with liensinine
(Figure 3(a)). Western blot analysis indicated that liensinine
downregulated Bcl-2 expression but did not change Bax
expression in MDA-MB-231 and MCF-7 cells, indicating
the decreased Bcl-2/Bax ratio. The expression levels of
procaspase-3 and full length PARP were dose-dependently
reduced and active caspase-3 and cleavedPARPwere detected
in breast cancer cells treated with 60 𝜇M liensinine (Fig-
ure 3(b)). Active caspase-3 was not detected in MCF-7 cells
in this study.
3.4. Liensinine and Nuciferine Inhibited RANKL-Induced
Osteoclast Formation and Function. When BMMswere incu-
bated in media with M-CSF in the presence of different con-
centrations of liensinine or nuciferine for 5 days, cell viability
was decreased in a dose-related manner (IC50 = 6.2 𝜇M for
liensinine and 79.3 𝜇Mfor nuciferine) (Figure 4(a)). RANKL-
induced osteoclast differentiation was inhibited by 57% by
liensinine at 5 𝜇M and by 56% by nuciferine at 20 𝜇M.
Liensinine (IC50 = 4.3𝜇M) showed more potent inhibition
on osteoclast formation than nuciferine (IC50 = 17.9 𝜇M)
(Figure 4(b)).
The effects of liensinine and nuciferine on the activity of
mature osteoclasts were investigated in BMMs treated with
liensinine or nuciferine at noncytotoxic concentrations for
2 additional days after the induction of osteoclast differen-
tiation by RANKL stimulation for 5 days. Treatment with
liensinine or nuciferine suppressed the formation of resorp-
tion pits in a dose-related manner. In particular, nuciferine
at 40 𝜇Mnoticeably inhibited the pit formation (Figure 4(c)).
The activity of cathepsin K in the culture media was dramat-
ically increased by RANKL stimulation but treatment with
liensinine at 7 𝜇M and nuciferine at 40 𝜇M suppressed the
RANKL-induced activity of cathepsin K by 86% and 71%,
respectively (Figure 4(d)). The secreted levels of pro-MMP-9
and active MMP-9 were also increased in RANKL-induced
mature osteoclasts but liensinine or nuciferine treatment
inhibited these increases (Figure 4(e)). MMP-2 activity did
not change by RANKL and two compounds.
3.5. Liensinine Blocked Breast Cancer-Induced Bone Loss in
Mice. We investigated in vivo inhibitory effect of liensinine
on breast cancer cell-mediated bone resorption. X-ray images
indicated that severe osteolytic lesion was produced in the
tibiae of mice inoculated with bone-tropic MDA-MB-231
breast cancer cells and treated with vehicle but orally admin-
istered liensinine inhibited the osteolysis (Figure 5(a)). Histo-
logical examination showed that the growth ofMDA-MB-231
breast cancer cells and osteolytic progression were substan-
tially increased in bone marrow of mice intratibially injected
withMDA-MB-231 breast cancer cells. Oral administration of
liensinine dose-dependently suppressed the increased tumor
growth and bone destruction (Figure 5(b)). In bonemorpho-
metric analysis using micro-CT, treatment with liensinine
inhibited decreases in the percentage of trabecular bone
volume (BV) to total volume (TV) of bone tissue (BV/TV),
the average thickness of trabecular bone (Tb.Th), and the
number of intersections between bone tissue and nonbone
components within a defined length of specimen (Tb.N) and
increases in the average width of the trabecular bone marrow
(Tb.Sp) and structure model index (SMI) as an index for the
ratio of plate-like to rod-like trabecular structures, compared
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Figure 2: Liensinine and nuciferine induced apoptosis and inhibited the proliferation in breast cancer cells. MDA-MB-231 or MCF-7 cells
were treated with various concentrations of liensinine and nuciferine in serum-free media for 24 h. (a) Apoptosis and necrosis were evaluated
with Cell Death Detection ELISA to detect DNA fragments in culture supernatants and cells lysates. (b) The amount of newly synthesized
DNA was assessed by BrdU incorporation assay. (c) The cells were fixed and stained with propidium iodide. The cell cycle distribution was
analyzed by flow cytometry. Data are expressed as the mean ± SE. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001 versus untreated cells.
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Figure 3: Liensinine inhibited Bcl-2 expression and induced apoptosis via caspase-dependent pathway in breast cancer cells. (a) MDA-MB-
231 or MCF-7 cells were cultured in serum-free media with the various concentrations of liensinine in the absence or presence of zVAD-fmk
(10𝜇M) for 24 h. Cell viability was determined with an MTT assay. Data are expressed as the mean ± SE. ∗𝑃 < 0.01 versus untreated cells
and #𝑃 < 0.01 versus liensinine alone-treated cells. (b) MDA-MB-231 and MCF-7 cells were treated with various concentrations of liensinine
for 24 h. Cell lysates were prepared and the levels of Bcl-2, Bax, procaspase-3 and active caspase-3, and full length and cleaved PARP were
detected by western blotting.
with vehicle treatment (Figure 5(c)). Serum levels of bone
resorption markers, TRAP5b and CTX, were also inhibited
in liensinine-treated mice (Figure 5(d)).
4. Discussion
Breast cancer has a property of metastasis to bone and
bone metastasis is one of main causes of decreased survival
rate in breast cancer patients. Once bone metastases grow
aggressively and interact with bone microenvironment, they
acquire the ability to penetrate the surrounding tissues and
to resorb bone matrix, causing severe osteolysis [19]. In this
study, we assessed whether liensinine and nuciferine, each
marker ingredient in lotus plumules and leaves [20], could
inhibit breast cancer cell-associated bone loss. The concen-
trations and doses for in vitro and in vivo experiments were
determined based on our preliminary experimental data.
Liensinine noticeably reduced the viability, migration,
and invasion of highly metastatic triple-negative MDA-MB-
231 and lessmetastatic estrogen receptor-positiveMCF-7 cells
in a dose-related manner. Nuciferine significantly inhibited
the viability and invasion of MDA-MB-231 cells rather than
MCF-7 cells but its inhibitory activity was less potent than
that of liensinine. By analyzing their inhibition levels on cell
viability, migration, and invasion, we found that the reduced
cell viability by liensinine and nuciferine treatment may
contribute to their inhibitory activities on cell migration and
invasion at noncytotoxic concentrations (less than 20 𝜇M).
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Figure 4: Liensinine and nuciferine inhibited RANKL-induced osteoclastogenesis and osteoclast-mediated bone resorption. (a) BMMs were
incubated in 10% FBS-𝛼-MEM containing M-CSF (30 ng/ml) and liensinine or nuciferine at various concentrations for 5 days. Cell viability
was determined by an MTT assay. Data are expressed as the means ± SE. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001 versus BMMs without test compounds.
(b) BMMswere treated with liensinine and nuciferine at the various concentrations in a presence ofM-CSF and RANKL. TRAP-positive cells
with >3 nuclei were counted as mature osteoclasts (100x). (c–e) BMMs were incubated in 10% FBS- 𝛼-MEM containing M-CSF (30 ng/ml)
and RANKL (100 ng/ml) on calcium phosphate-coated plates for 5 days and then treated with liensinine or nuciferine for an additional 2
days. (c) After cell lysis, the pit area was observed under light microscopy (×100). (d) Cathepsin K levels in the collected culture media were
measured using the SensiZyme Cathepsin K Activity Kit. (e) Gelatinolytic activities of MMPs in the collected culture media were detected
by zymography and visualized as clear bands against the blue background. Data are expressed as the means ± SE. #𝑃 < 0.001 versus BMMs
without RANKL. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001 versus BMMs with RANKL alone.
Because proliferation and apoptosis are the important regula-
tory mechanisms of cell growth [21], we further investigated
whether these active compounds could induce apoptotic cell
death and/or block cell proliferation. In particular, liensinine
noticeably induced apoptosis in MDA-MB-231 cells rather
than in MCF-7 cells. Nuciferine also induced apoptosis in
both breast cancer cell lines. Necrosis was not observed in our
experimental conditions. Liensinine and nuciferine inhibited
BrdU incorporation into the newly synthesized DNA for cell
proliferation in two breast cancer cell lines. In flow cytometric
analysis, liensinine treatment clearly increased sub-G1 peak
as an indicator of apoptotic cell death and induced cell
cycle arrest at G2/M phase in MDA-MB-231 and MCF-7
cells compared with nuciferine treatment. These results may
indicate that liensinine and nuciferine inhibit cell growth by
inducing apoptotic cell death and arresting cell cycle in breast
cancer cells. Liensinine may be more potent than nuciferine
andmore effective in the induction of apoptosis inMDA-MB-
231 cells than MCF-7 cells. In addition, we confirmed that
liensinine induces apoptosis via mitochondrial-dependent
pathway as supported by the decreased Bcl-2/Bax ratio, the
activation of caspase-3, and caspase-mediated cleavage of
PARP.
When the breast cancer cells spread to the bone, can-
cer cell-released osteolytic factors stimulate osteoclastogen-
esis directly or by promoting osteoblastic/stromal RANKL
expression [22]. The differentiated osteoclasts cause bone
resorption by dissolving inorganic calcium hydroxyapatite
in acidic conditions and organic bone matrix by MMPs and
cathepsin K [23–25]. In this study, liensinine and nuciferine
treatment inhibited RANKL-induced osteoclast differenti-
ation and bone resorption by decreasing the secretion of
cathepsin K and MMP-9 at nontoxic concentrations. These
results suggest that liensinine and nuciferine can block
RANKL-induced osteoclast formation and function. Further-
more, antibone resorptive activities of these compounds can
contribute to the inhibited growth of bone metastases by
blocking the release of bone-storing growth factors.
Finally, we tested the inhibitory effect of liensinine on
breast cancer-mediated bone loss in the mice with intratibial
injection ofMDA-MB-231 cells. Oral administration of liensi-
nine reduced osteolytic lesions in mouse tibiae, as supported
by histological examination, bonemorphometric parameters,
and serum biochemical markers of bone resorption, TRAP5b
and CTX.
Collectively, liensinine and nuciferine inhibited cell pro-
liferation, migration, and invasion and especially induced
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Figure 5: Liensinine prevented breast cancer-induced bone loss inmice.MDA-MB-231 cells were injected into the tibiae of nudemice (𝑛 = 6).
Liensinine was administered orally five times per week and zoledronic acid (0.1mg/kg) was injected subcutaneously 3 times per week for 5
weeks. (a) Experimental design. (b) X-ray images were taken on week 5. (c) Serial sections of mouse tibiae and femora were stained with
hematoxylin-eosin. Tm: tumor mass, BM: bone marrow, Fm: femur, and Tb: tibia. (d) Bone morphometric parameters, BV/TV (%), Tb.Th
(mm), Tb.N (1/mm), Tb.Sp (mm), and SMI, were analyzed with micro-CT. (e) Serum bone resorption markers, TRAP5b and CTX, were
analyzed using the respective kits. Data are expressed as the means ± SE. #𝑃 < 0.05 and ##𝑃 < 0.01 versus control mice without MDA-MB-231
cells; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001 versus cancer cell-inoculated mice with vehicle (PBS containing 1% DMSO) alone.
apoptosis via mitochondrial-dependent pathway in breast
cancer cells. These compounds prevented bone resorption by
inhibiting the formation and function of osteoclast. There-
fore, liensinine and nuciferine may be promising protective
and therapeutic agents for patients with breast cancer and
the related bone loss. In the further study, we will investigate
whether liensinine and nuciferine can activate osteoblastic
cells.
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